Philip J. Barr, Ph.D., is currently the President and Chief Operating Officer and a Director of Arriva Pharmaceuticals, Inc., an Alameda, California-based biotechnology company. Dr. Barr has also been an Adjunct Professor of Pharmaceutical Chemistry at the University of California, San Francisco since 1985. Arriva focuses on biopharmaceuticals via pulmonary administration for the treatment of emphysema, asthma and cystic fibrosis. Other current scientific and commercial interests of Dr. Barr include: production and manufacture of recombinant proteins in yeast; the treatment of respiratory diseases using protease inhibitors; and recombinant proteins for oncology applications.

From his experience and involvement in commercial biotechnology since the early 1980s, Dr. Barr has a unique and valuable perspective on current platform technologies within the biotechnology field, and is highly proficient in evaluating emerging technologies in the biomedical area. Having been the former Director of Molecular Biology of Chiron Corporation, he has particular expertise in the production of biopharmaceutical products for the treatment and diagnosis of human disease.

Dr. Barr is a citizen of the U.K., and has permanent residence status in the US. He holds a B.Sc. (Hons) and Ph.D. in Chemistry, University of Birmingham, U.K. (1975, 1978), and won a Post-Doctoral Scholarship in Chemistry, University of Alberta, Canada, a Post-Doctoral Fellowship in Pharmaceutical Chemistry, University of California, San Francisco. He has published over 180 peer-reviewed articles in the scientific literature, and is named as an inventor on 27 issued U.S. patents.